Polyrotaxane Composition for Cholesterol Removal and Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for treating lipid metabolism disorders and autophagy dysfunctions, such as Niemann-Pick Type C disease, face challenges due to short blood half-life, rapid renal excretion, and side effects like hemolytic activity, making it difficult to achieve a high therapeutic effect with cyclodextrins.
Innovation Solution
A pharmaceutical composition comprising a polyrotaxane with a plurality of cyclic molecules threaded by a linear molecule linked via intracellularly degradable linkages at both ends, specifically a copolymer of polyethylene glycol and polypropylene glycol, effectively enhancing cholesterol removal and autolysosome formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If cyclodextrins are administered to achieve sufficient therapeutic effect, then cholesterol removal effect is improved, but blood half-life is shortened and renal excretion increases
Solution Approach 1:
The patent applies composite materials by combining cyclodextrin molecules with a linear water-soluble polymer to form a polyrotaxane structure. This composite structure allows the cyclodextrin to maintain its cholesterol removal capability while the polymer component extends the blood half-life and reduces renal excretion, thereby resolving the contradiction between therapeutic effect and duration of action.
2Quantity of substance
If highly concentrated cyclodextrin is administered to achieve sufficient therapeutic effect, then cholesterol removal effect is improved, but hemolytic activity and tissue damage increase
Solution Approach 1:
The polyrotaxane composite structure modifies the properties of cyclodextrin by incorporating it into a polymer matrix. This composite approach reduces the hemolytic activity and tissue damage associated with high concentrations of free cyclodextrin while preserving the cholesterol removal effect, thus resolving the contradiction between therapeutic efficacy and safety.
3Reliability
If cyclodextrin is administered to treat lipid metabolism disorders, then therapeutic effect is improved, but rapid renal excretion occurs
Solution Approach 1:
By forming a polyrotaxane composite where cyclodextrin is threaded on a linear polymer, the patent increases the molecular weight and alters the pharmacokinetic properties. This composite structure reduces renal excretion while maintaining the therapeutic effect, resolving the contradiction between reliability of treatment and substance loss through excretion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyrotaxane composition provides a safer, more effective cholesterol removal and enhanced autolysosome formation, reducing side effects and extending blood half-life, thereby improving therapeutic outcomes for lipid metabolism and autophagy-related disorders.
Implementation Method 1
the linear molecule is linked to bulky substituents via intracellularly degradable linkages at both ends
Data Source
AI summary
A medicinal composition for diseases caused by dyslipidemia and/or autophagy dysfunction, etc., said medicinal composition comprising polyrotaxane that carries bulky substituents introduced, via intracellularly degradable bonds, into both ends of a linear molecule penetrating through plural cyclic molecules.